1
|
Li XY, Liu SH, Liu C, Zu HM, Guo XQ, Xiang HL, Huang Y, Yan ZL, Li YJ, Sun J, Song RX, Yan JQ, Ye Q, Liu F, Huang L, Meng FP, Zhang XN, Yang SS, Hu SJ, Ruan JG, Li YL, Wang NN, Cui HP, Wang YM, Lei C, Wang QH, Tian HL, Qu ZS, Yuan M, Shi RC, Yang XT, Jin D, Su D, Liu YJ, Chen Y, Xia YX, Li YZ, Yang QH, Li H, Zhao XL, Tian ZM, Yu HJ, Zhang XJ, Wu CX, Wu ZJ, Li SS, Shen Q, Liu XM, Hu JP, Wu MQ, Dang T, Wang J, Meng XM, Wang HY, Jiang ZY, Liu YY, Liu Y, Qu SX, Tao H, Yan DM, Liu J, Fu W, Yu J, Wang FS, Qi XL, Fu JL. [Impact of different diagnostic criteria for assessing mild micro-hepatic encephalopathy in liver cirrhosis: an analysis based on a prospective, multicenter, real-world study]. Zhonghua Gan Zang Bing Za Zhi 2023; 31:961-968. [PMID: 37872092 DOI: 10.3760/cma.j.cn501113-20220602-00298] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 10/25/2023]
Abstract
Objective: To compare the differences in the prevalence of mild micro-hepatic encephalopathy (MHE) among patients with cirrhosis by using the psychometric hepatic encephalopathy score (PHES) and the Stroop smartphone application (Encephal App) test. Methods: This prospective, multi-center, real-world study was initiated by the National Clinical Medical Research Center for Infectious Diseases and the Portal Hypertension Alliance and registered with International ClinicalTrials.gov (NCT05140837). 354 cases of cirrhosis were enrolled in 19 hospitals across the country. PHES (including digital connection tests A and B, digital symbol tests, trajectory drawing tests, and serial management tests) and the Stroop test were conducted in all of them. PHES was differentiated using standard diagnostic criteria established by the two studies in China and South Korea. The Stroop test was evaluated based on the criteria of the research and development team. The impact of different diagnostic standards or methods on the incidence of MHE in patients with cirrhosis was analyzed. Data between groups were differentiated using the t-test, Mann-Whitney U test, and χ (2) test. A kappa test was used to compare the consistency between groups. Results: After PHES, the prevalence of MHE among 354 cases of cirrhosis was 78.53% and 15.25%, respectively, based on Chinese research standards and Korean research normal value standards. However, the prevalence of MHE was 56.78% based on the Stroop test, and the differences in pairwise comparisons among the three groups were statistically significant (kappa = -0.064, P < 0.001). Stratified analysis revealed that the MHE prevalence in three groups of patients with Child-Pugh classes A, B, and C was 74.14%, 83.33%, and 88.24%, respectively, according to the normal value standards of Chinese researchers, while the MHE prevalence rates in three groups of patients with Child-Pugh classes A, B, and C were 8.29%, 23.53%, and 38.24%, respectively, according to the normal value standards of Korean researchers. Furthermore, the prevalence rates of MHE in the three groups of patients with Child-Pugh grades A, B, and C were 52.68%, 58.82%, and 73.53%, respectively, according to the Stroop test standard. However, among the results of each diagnostic standard, the prevalence of MHE showed an increasing trend with an increasing Child-Pugh grade. Further comparison demonstrated that the scores obtained by the number connection test A and the number symbol test were consistent according to the normal value standards of the two studies in China and South Korea (Z = -0.982, -1.702; P = 0.326, 0.089), while the other three sub-tests had significant differences (P < 0.001). Conclusion: The prevalence rate of MHE in the cirrhotic population is high, but the prevalence of MHE obtained by using different diagnostic criteria or methods varies greatly. Therefore, in line with the current changes in demographics and disease spectrum, it is necessary to enroll a larger sample size of a healthy population as a control. Moreover, the establishment of more reliable diagnostic scoring criteria will serve as a basis for obtaining accurate MHE incidence and formulating diagnosis and treatment strategies in cirrhotic populations.
Collapse
Affiliation(s)
- X Y Li
- Senior Department of Infectious Diseases, the Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing 100039, China Medical School of Chinese PLA, Beijing 100853, China
| | - S H Liu
- The First School of Clinical Medicine of Lanzhou University, Lanzhou 730000, China
| | - C Liu
- Department of Radiology, Affiliated Zhongda Hospital, Southeast University, Nanjing 210000, China
| | - H M Zu
- Department of Gastroenterology, Qinghai Provincial Fourth People's Hospital, Xining 810000, China
| | - X Q Guo
- Department of Hepatology, the Third People's Hospital of Taiyuan, Taiyuan 030000, China
| | - H L Xiang
- Department of Gastroenterology and Hepatology, Tianjin Third Central Hospital, Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, Artificial Cell Engineering Technology Research Center, Institute of Hepatobiliary Disease, Tianjin 300000, China
| | - Y Huang
- Department of Infectious Diseases, Hunan Key Laboratory of Viral Hepatitis, Xiangya Hospital, Central South University, Changsha 410000, China
| | - Z L Yan
- Department of Gastroenterology, Qinghai Provincial Fourth People's Hospital, Xining 810000, China
| | - Y J Li
- Department of Gastroenterology, Qinghai Provincial Fourth People's Hospital, Xining 810000, China
| | - J Sun
- Department of Hepatology, the Third People's Hospital of Taiyuan, Taiyuan 030000, China
| | - R X Song
- Department of Gastroenterology and Hepatology, Tianjin Third Central Hospital, Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, Artificial Cell Engineering Technology Research Center, Institute of Hepatobiliary Disease, Tianjin 300000, China
| | - J Q Yan
- Department of Gastroenterology and Hepatology, Tianjin Third Central Hospital, Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, Artificial Cell Engineering Technology Research Center, Institute of Hepatobiliary Disease, Tianjin 300000, China
| | - Q Ye
- Department of Gastroenterology and Hepatology, Tianjin Third Central Hospital, Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, Artificial Cell Engineering Technology Research Center, Institute of Hepatobiliary Disease, Tianjin 300000, China
| | - F Liu
- Department of Infectious Diseases, Hunan Key Laboratory of Viral Hepatitis, Xiangya Hospital, Central South University, Changsha 410000, China
| | - L Huang
- Senior Department of Infectious Diseases, the Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing 100039, China Medical School of Chinese PLA, Beijing 100853, China
| | - F P Meng
- Senior Department of Infectious Diseases, the Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing 100039, China Medical School of Chinese PLA, Beijing 100853, China
| | - X N Zhang
- Medical School of Chinese PLA, Beijing 100853, China
| | - S S Yang
- Department of Gastroenterology, General Hospital of Ningxia Medical University, Yinchuan 750000, China
| | - S J Hu
- Department of Gastroenterology, People's Hospital of Ningxia Hui Autonomous Region, Yinchuan 750000, China
| | - J G Ruan
- Branch Hospital for Diseases of the Heart, Brain, and Blood Vessels of General Hospital of Ningxia Medical University, Yinchuan 750000, China
| | - Y L Li
- Department of Gastroenterology, the First Affiliated Hospital of China Medical University, Shenyang 110000, China
| | - N N Wang
- Department of Gastroenterology, the First Affiliated Hospital of China Medical University, Shenyang 110000, China
| | - H P Cui
- Department of Gastroenterology, the First Affiliated Hospital of China Medical University, Shenyang 110000, China
| | - Y M Wang
- Department of Gastroenterology, the First Affiliated Hospital of China Medical University, Shenyang 110000, China
| | - C Lei
- Department of Hepatology, the First People's Hospital of Changde City, Changde 415000, China
| | - Q H Wang
- Department of Hepatology, the First People's Hospital of Changde City, Changde 415000, China
| | - H L Tian
- Department of Hepatology, the First People's Hospital of Changde City, Changde 415000, China
| | - Z S Qu
- Department of Infectious Diseases, Xiangxi People's Hospital, Jishou 416000, China
| | - M Yuan
- Department of Infectious Diseases, Xiangxi People's Hospital, Jishou 416000, China
| | - R C Shi
- Department of Gastroenterology, Wuzhong People's Hospital, Wuzhong 751100, China
| | - X T Yang
- Department of Gastroenterology, Wuzhong People's Hospital, Wuzhong 751100, China
| | - D Jin
- Department of Gastroenterology, Wuzhong People's Hospital, Wuzhong 751100, China
| | - D Su
- Department of Gastroenterology, Wuzhong People's Hospital, Wuzhong 751100, China
| | - Y J Liu
- Department of Hepatology, Hunan Provinces Directly Affiliated Traditional Chinese Medicine Hospital, Zhuzhou 412000, China
| | - Y Chen
- Department of Hepatology, Hunan Provinces Directly Affiliated Traditional Chinese Medicine Hospital, Zhuzhou 412000, China
| | - Y X Xia
- Department of Hepatology, Hunan Provinces Directly Affiliated Traditional Chinese Medicine Hospital, Zhuzhou 412000, China
| | - Y Z Li
- Department of Infectious Diseases, the First People's Hospital, Huaihua City, Huaihua 418000, China
| | - Q H Yang
- Department of Infectious Diseases, the First People's Hospital, Huaihua City, Huaihua 418000, China
| | - H Li
- Department of Infectious Diseases, the First People's Hospital, Huaihua City, Huaihua 418000, China
| | - X L Zhao
- Department of Hepatology, Chongqing Public Health Medical Center, Chongqing 400000, China
| | - Z M Tian
- Department of Hepatology, Chongqing Public Health Medical Center, Chongqing 400000, China
| | - H J Yu
- Department of Hepatology, Chongqing Public Health Medical Center, Chongqing 400000, China
| | - X J Zhang
- Department of Hepatology, Chongqing Public Health Medical Center, Chongqing 400000, China
| | - C X Wu
- Liver Disease Diagnosis and Treatment Center, the Fourth People's Hospital of Yiyang City, Yiyang 413000, China
| | - Z J Wu
- Liver Disease Diagnosis and Treatment Center, the Fourth People's Hospital of Yiyang City, Yiyang 413000, China
| | - S S Li
- Liver Disease Diagnosis and Treatment Center, the Fourth People's Hospital of Yiyang City, Yiyang 413000, China
| | - Q Shen
- Department of Gastroenterology, Yinchuan Second People's Hospital, Yinchuan 750000, China
| | - X M Liu
- Department of Gastroenterology, Yinchuan Second People's Hospital, Yinchuan 750000, China
| | - J P Hu
- Department of Gastroenterology, Yinchuan First People's Hospital, Yinchuan 750000, China
| | - M Q Wu
- Department of Gastroenterology, Yinchuan First People's Hospital, Yinchuan 750000, China
| | - T Dang
- Department of Gastroenterology, the Second Affiliated Hospital of Baotou Medical College, Baotou 014000, China
| | - J Wang
- Department of Gastroenterology, the Second Affiliated Hospital of Baotou Medical College, Baotou 014000, China
| | - X M Meng
- Department of Gastroenterology, the Second Affiliated Hospital of Baotou Medical College, Baotou 014000, China
| | - H Y Wang
- Department of Gastroenterology, the Second Affiliated Hospital of Baotou Medical College, Baotou 014000, China
| | - Z Y Jiang
- Department of Gastroenterology, the Second Affiliated Hospital of Baotou Medical College, Baotou 014000, China
| | - Y Y Liu
- Department of Gastroenterology, Dandong Central Hospital, Dandong 118000, China
| | - Y Liu
- Department of Gastroenterology, Dandong Central Hospital, Dandong 118000, China
| | - S X Qu
- Department of Gastroenterology, Dandong Central Hospital, Dandong 118000, China
| | - H Tao
- Department of Gastroenterology, Dandong Central Hospital, Dandong 118000, China
| | - D M Yan
- Department of Hepatology, Shenyang 739 Hospital, Shenyang 110000, China
| | - J Liu
- Department of Hepatology, Shenyang 739 Hospital, Shenyang 110000, China
| | - W Fu
- Department of Hepatology, Shenyang 739 Hospital, Shenyang 110000, China
| | - J Yu
- Department of Hepatology, Shenyang 739 Hospital, Shenyang 110000, China
| | - F S Wang
- Senior Department of Infectious Diseases, the Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing 100039, China Medical School of Chinese PLA, Beijing 100853, China
| | - X L Qi
- The First School of Clinical Medicine of Lanzhou University, Lanzhou 730000, China Department of Radiology, Affiliated Zhongda Hospital, Southeast University, Nanjing 210000, China
| | - J L Fu
- Medical School of Chinese PLA, Beijing 100853, China Department of Infectious Diseases, the Fifth Medical Center of Chinese PLA General Hospital, Beijing 100039, China
| |
Collapse
|
2
|
Xu F, Bian Y, Zhang GQ, Gao LY, Liu YF, Liu TX, Li G, Song RX, Su LJ, Zhou YJ, Cui JY, Yan XL, Guo FM, Zhang HY, Li QH, Zhao M, Ma LK, You BA, Wang G, Kong L, Ma JL, Zhou XF, Chang ZL, Tang ZY, Yu DY, Cheng K, Xue L, Li X, Pang JJ, Wang JL, Zhang HT, Yu XZ, Chen YG. [Safety and efficacy of the early administration of levosimendan in patients with acute non-ST-segment elevation myocardial infarction and elevated NT-proBNP levels: An Early Management Strategy of Acute Heart Failure (EMS-AHF)]. Zhonghua Nei Ke Za Zhi 2023; 62:374-383. [PMID: 37032132 DOI: 10.3760/cma.j.cn112138-20220420-00284] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Subscribe] [Scholar Register] [Indexed: 04/11/2023]
Abstract
Objectives: To investigated the safety and efficacy of treating patients with acute non-ST-segment elevation myocardial infarction (NSTEMI) and elevated levels of N-terminal pro-hormone B-type natriuretic peptide (NT-proBNP) with levosimendan within 24 hours of first medical contact (FMC). Methods: This multicenter, open-label, block-randomized controlled trial (NCT03189901) investigated the safety and efficacy of levosimendan as an early management strategy of acute heart failure (EMS-AHF) for patients with NSTEMI and high NT-proBNP levels. This study included 255 patients with NSTEMI and elevated NT-proBNP levels, including 142 males and 113 females with a median age of 65 (58-70) years, and were admitted in the emergency or outpatient departments at 14 medical centers in China between October 2017 and October 2021. The patients were randomly divided into a levosimendan group (n=129) and a control group (n=126). The primary outcome measure was NT-proBNP levels on day 3 of treatment and changes in the NT-proBNP levels from baseline on day 5 after randomization. The secondary outcome measures included the proportion of patients with more than 30% reduction in NT-proBNP levels from baseline, major adverse cardiovascular events (MACE) during hospitalization and at 6 months after hospitalization, safety during the treatment, and health economics indices. The measurement data parameters between groups were compared using the t-test or the non-parametric test. The count data parameters were compared between groups using the χ² test. Results: On day 3, the NT-proBNP levels in the levosimendan group were lower than the control group but were statistically insignificant [866 (455, 1 960) vs. 1 118 (459, 2 417) ng/L, Z=-1.25,P=0.21]. However, on day 5, changes in the NT-proBNP levels from baseline in the levosimendan group were significantly higher than the control group [67.6% (33.8%,82.5%)vs.54.8% (7.3%,77.9%), Z=-2.14, P=0.03]. There were no significant differences in the proportion of patients with more than 30% reduction in the NT-proBNP levels on day 5 between the levosimendan and the control groups [77.5% (100/129) vs. 69.0% (87/126), χ²=2.34, P=0.13]. Furthermore, incidences of MACE did not show any significant differences between the two groups during hospitalization [4.7% (6/129) vs. 7.1% (9/126), χ²=0.72, P=0.40] and at 6 months [14.7% (19/129) vs. 12.7% (16/126), χ²=0.22, P=0.64]. Four cardiac deaths were reported in the control group during hospitalization [0 (0/129) vs. 3.2% (4/126), P=0.06]. However, 6-month survival rates were comparable between the two groups (log-rank test, P=0.18). Moreover, adverse events or serious adverse events such as shock, ventricular fibrillation, and ventricular tachycardia were not reported in both the groups during levosimendan treatment (days 0-1). The total cost of hospitalization [34 591.00(15 527.46,59 324.80) vs. 37 144.65(16 066.90,63 919.00)yuan, Z=-0.26, P=0.80] and the total length of hospitalization [9 (8, 12) vs. 10 (7, 13) days, Z=0.72, P=0.72] were lower for patients in the levosimendan group compared to those in the control group, but did not show statistically significant differences. Conclusions: Early administration of levosimendan reduced NT-proBNP levels in NSTEMI patients with elevated NT-proBNP and did not increase the total cost and length of hospitalization, but did not significantly improve MACE during hospitalization or at 6 months.
Collapse
Affiliation(s)
- F Xu
- Department of Emergency Medicine, Qilu Hospital of Shandong University, Acute Heart Failure Unit (AHFU), Shandong Provincial Clinical Research Center for Emergency and Critical Care Medicine, Institute of Emergency and Critical Care Medicine of Shandong University, Key Laboratory of Emergency and Critical Care Medicine of Shandong Province, Key Laboratory of Cardiopulmonary-Cerebral Resuscitation Research of Shandong Province, Shandong Provincial Engineering Laboratory for Emergency and Critical Care Medicine, Jinan 250012, China
| | - Y Bian
- Department of Emergency Medicine, Cheeloo College of Medicine, Shandong University, Jinan 250012, China
| | - G Q Zhang
- Department of Emergency, China-Japan Friendship Hospital, Beijing 100029, China
| | - L Y Gao
- Department of Emergency Medicine, Qilu Hospital of Shandong University, Acute Heart Failure Unit (AHFU), Shandong Provincial Clinical Research Center for Emergency and Critical Care Medicine, Institute of Emergency and Critical Care Medicine of Shandong University, Key Laboratory of Emergency and Critical Care Medicine of Shandong Province, Key Laboratory of Cardiopulmonary-Cerebral Resuscitation Research of Shandong Province, Shandong Provincial Engineering Laboratory for Emergency and Critical Care Medicine, Jinan 250012, China
| | - Y F Liu
- Department of Emergency, Zibo Central Hospital, Zibo 255036, China
| | - T X Liu
- Department of Emergency, Weifang People's Hospital, Weifang 261041, China
| | - G Li
- Department of Emergency, China-Japan Friendship Hospital, Beijing 100029, China
| | - R X Song
- Department of Emergency Medicine, Qilu Hospital of Shandong University, Acute Heart Failure Unit (AHFU), Shandong Provincial Clinical Research Center for Emergency and Critical Care Medicine, Institute of Emergency and Critical Care Medicine of Shandong University, Key Laboratory of Emergency and Critical Care Medicine of Shandong Province, Key Laboratory of Cardiopulmonary-Cerebral Resuscitation Research of Shandong Province, Shandong Provincial Engineering Laboratory for Emergency and Critical Care Medicine, Jinan 250012, China
| | - L J Su
- Department of Emergency, Zibo Central Hospital, Zibo 255036, China
| | - Y J Zhou
- Department of Emergency, Weifang People's Hospital, Weifang 261041, China
| | - J Y Cui
- Department of Cardiology, Binzhou People's Hospital, Binzhou 256600, China
| | - X L Yan
- Emergency Medicine Department, the Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, China
| | - F M Guo
- Department of Cardiology, Yantaishan Hospital, Yantai 264003,China
| | - H Y Zhang
- Department of Cardiology, the Central Hospital of Taian, Taian 271000, China
| | - Q H Li
- Department of Cardiology, Shenli Oilfield Central Hospital, Dongying 257000, China
| | - M Zhao
- Department of Emergency Medicine, Shengjing Hospital of China Medical University, Shenyang 110004, China
| | - L K Ma
- Department of Cardiology, the First Affiliated Hospital of USTC (Anhui Provincial Hospital), Hefei 230001, China
| | - B A You
- Department of Cardiology, Qilu Hospital of Shandong University (Qingdao), Qingdao 266031, China
| | - G Wang
- Department of Emergency Medicine, Qilu Hospital of Shandong University (Qingdao), Qingdao 266031, China
| | - L Kong
- Department of Emergency Center, Affiliated Hospital, Shandong University of Traditional Chinese Medicine, Jinan 250011, China
| | - J L Ma
- Department of Emergency Center, Affiliated Hospital, Shandong University of Traditional Chinese Medicine, Jinan 250011, China
| | - X F Zhou
- Department of Cardiology, Weihai Municipal Hospital, Weihai 264200, China
| | - Z L Chang
- Department of Emergency Medicine, Qilu Hospital of Shandong University, Acute Heart Failure Unit (AHFU), Shandong Provincial Clinical Research Center for Emergency and Critical Care Medicine, Institute of Emergency and Critical Care Medicine of Shandong University, Key Laboratory of Emergency and Critical Care Medicine of Shandong Province, Key Laboratory of Cardiopulmonary-Cerebral Resuscitation Research of Shandong Province, Shandong Provincial Engineering Laboratory for Emergency and Critical Care Medicine, Jinan 250012, China
| | - Z Y Tang
- Department of Emergency Medicine, Qilu Hospital of Shandong University, Acute Heart Failure Unit (AHFU), Shandong Provincial Clinical Research Center for Emergency and Critical Care Medicine, Institute of Emergency and Critical Care Medicine of Shandong University, Key Laboratory of Emergency and Critical Care Medicine of Shandong Province, Key Laboratory of Cardiopulmonary-Cerebral Resuscitation Research of Shandong Province, Shandong Provincial Engineering Laboratory for Emergency and Critical Care Medicine, Jinan 250012, China
| | - D Y Yu
- Department of Emergency Medicine, Qilu Hospital of Shandong University, Acute Heart Failure Unit (AHFU), Shandong Provincial Clinical Research Center for Emergency and Critical Care Medicine, Institute of Emergency and Critical Care Medicine of Shandong University, Key Laboratory of Emergency and Critical Care Medicine of Shandong Province, Key Laboratory of Cardiopulmonary-Cerebral Resuscitation Research of Shandong Province, Shandong Provincial Engineering Laboratory for Emergency and Critical Care Medicine, Jinan 250012, China
| | - K Cheng
- Department of Emergency Medicine, Qilu Hospital of Shandong University, Acute Heart Failure Unit (AHFU), Shandong Provincial Clinical Research Center for Emergency and Critical Care Medicine, Institute of Emergency and Critical Care Medicine of Shandong University, Key Laboratory of Emergency and Critical Care Medicine of Shandong Province, Key Laboratory of Cardiopulmonary-Cerebral Resuscitation Research of Shandong Province, Shandong Provincial Engineering Laboratory for Emergency and Critical Care Medicine, Jinan 250012, China
| | - L Xue
- Department of Emergency Medicine, Qilu Hospital of Shandong University, Acute Heart Failure Unit (AHFU), Shandong Provincial Clinical Research Center for Emergency and Critical Care Medicine, Institute of Emergency and Critical Care Medicine of Shandong University, Key Laboratory of Emergency and Critical Care Medicine of Shandong Province, Key Laboratory of Cardiopulmonary-Cerebral Resuscitation Research of Shandong Province, Shandong Provincial Engineering Laboratory for Emergency and Critical Care Medicine, Jinan 250012, China
| | - X Li
- Department of Emergency Medicine, Qilu Hospital of Shandong University, Acute Heart Failure Unit (AHFU), Shandong Provincial Clinical Research Center for Emergency and Critical Care Medicine, Institute of Emergency and Critical Care Medicine of Shandong University, Key Laboratory of Emergency and Critical Care Medicine of Shandong Province, Key Laboratory of Cardiopulmonary-Cerebral Resuscitation Research of Shandong Province, Shandong Provincial Engineering Laboratory for Emergency and Critical Care Medicine, Jinan 250012, China
| | - J J Pang
- Department of Emergency Medicine, Qilu Hospital of Shandong University, Acute Heart Failure Unit (AHFU), Shandong Provincial Clinical Research Center for Emergency and Critical Care Medicine, Institute of Emergency and Critical Care Medicine of Shandong University, Key Laboratory of Emergency and Critical Care Medicine of Shandong Province, Key Laboratory of Cardiopulmonary-Cerebral Resuscitation Research of Shandong Province, Shandong Provincial Engineering Laboratory for Emergency and Critical Care Medicine, Jinan 250012, China
| | - J L Wang
- Department of Emergency Medicine, Qilu Hospital of Shandong University, Acute Heart Failure Unit (AHFU), Shandong Provincial Clinical Research Center for Emergency and Critical Care Medicine, Institute of Emergency and Critical Care Medicine of Shandong University, Key Laboratory of Emergency and Critical Care Medicine of Shandong Province, Key Laboratory of Cardiopulmonary-Cerebral Resuscitation Research of Shandong Province, Shandong Provincial Engineering Laboratory for Emergency and Critical Care Medicine, Jinan 250012, China
| | - H T Zhang
- Department of Surgical Intensive Care Unit, Fuwai Hospital, National Center for Cardiovascular Diseases, Beijing 100037, China
| | - X Z Yu
- Department of Emergency, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Science, Beijing 100730, China
| | - Y G Chen
- Department of Emergency Medicine, Qilu Hospital of Shandong University, Acute Heart Failure Unit (AHFU), Shandong Provincial Clinical Research Center for Emergency and Critical Care Medicine, Institute of Emergency and Critical Care Medicine of Shandong University, Key Laboratory of Emergency and Critical Care Medicine of Shandong Province, Key Laboratory of Cardiopulmonary-Cerebral Resuscitation Research of Shandong Province, Shandong Provincial Engineering Laboratory for Emergency and Critical Care Medicine, Jinan 250012, China
| |
Collapse
|
3
|
Li XL, Song RX, Lin X, Ma RX, Bai F, Yu J. Comparison of calycosin and irbesartan for their impact on renin angiotensin system in human umbilical vein endothelial cell. Minerva Med 2015; 106:9-16. [PMID: 25423498] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
AIM The aim of this paper was to compare the efficacy of in vitro calycosin and irbesartan for the treatment of angiotensin II (AngII)-induced renin angiotensin system (RAS) disorder in human umbilical vein endothelial cells (HUVECs). METHODS Cultured HUVECs were randomly divided into several groups: control, AngII 1×10-6 mol) alone, Ang II (1×10-6 mol) plus calycosin (0.1, 1, 10 mg/L) and Ang II (1×10-6 mol) plus Irbesartan (10 μmol). Morphology of vascular endothelial cells was studied by using a light microscope with hematoxylin and eosin double staining. Changes in both protein and gene expression of Angiotensin-converting enzyme (ACE) and angiotensin-converting enzyme 2 (ACE2) were detected by immunohistochemistry analysis and reverse transcription polymerase chain reaction (RT-PCR) techniques, respectively. RESULTS In comparison to control, AngII significantly promoted both protein and gene expressions of ACE while inhibited those of ACE2 in HUVECs. Interestingly, Calycosin was able to inhibit the effect of AngII in a concentration dependent manner, and its effect at concentration of 35 μmol was equal to that of positive control Irbesartan (10μmol). CONCLUSION Calycosin from Radix Astragali from Gansu province could protect HUVECs from AngII induced RAS disorder by downregulation of ACE expression and increased ACE2 expression, which is similar to irbesartan. These results suggest that calycosin may be a promising candidate for treatment of endothelial dysfunction.
Collapse
Affiliation(s)
- X L Li
- Department of Cardiology The Second Hospital of Lanzhou University Lanzhou, China -
| | | | | | | | | | | |
Collapse
|
4
|
Xiong YM, Mo XY, Zou XZ, Song RX, Sun WY, Lu W, Chen Q, Yu YX, Zang WJ. Association study between polymorphisms in selenoprotein genes and susceptibility to Kashin-Beck disease. Osteoarthritis Cartilage 2010; 18:817-24. [PMID: 20178852 DOI: 10.1016/j.joca.2010.02.004] [Citation(s) in RCA: 91] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/10/2009] [Revised: 01/27/2010] [Accepted: 02/09/2010] [Indexed: 02/02/2023]
Abstract
OBJECTIVES Kashin-Beck disease (KBD) is a disabling osteoarthropathy involving growth cartilage endemic to selenium (Se)-deficient regions in China. Associations between genetic variation in selenoprotein genes and susceptibility to many diseases have recently been investigated but few studies have been performed on KBD. We found four genetic polymorphisms in selenoprotein genes and assessed their association with increased susceptibility to KBD. METHODS Four polymorphisms including GPX1 (rs1050450), TrxR2 (rs5748469), SEPP1 (rs7579) and DIO2 (rs225014) were analyzed for 161 KBD patients and 312 controls using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) or tetra-primer amplification refractory mutation system PCR (Tetra-primer ARMS PCR). Glutathione peroxidase (GPX) activity in whole blood was measured using a GPX assay kit. The mRNA expression of GPX1, nuclear factor-kappaB (NF-kappaB) p65 and p53 in both whole blood and articular cartilage tissue were detected using Real-Time PCR. RESULTS The genotypic and allelic frequency of GPX1 Pro198Leu was significantly different between KBD patients and controls (P=0.013, P=0.037). A significant increased KBD risk was observed in individuals with Pro/Leu or Leu/Leu (odds ratio=1.781; 95% confidence interval: 1.127-2.814) compared with Pro/Pro. No association was observed between the other three single nucleotide polymorphisms (SNPs) and KBD risk. In addition, GPX enzyme activity in whole blood was lower in the KBD group (P<0.01), and the GPX activity in whole blood decreased significantly in a subgroup of individuals representing Pro/Leu and Leu/Leu compared to Pro/Pro (P<0.01). In whole blood and articular cartilage tissue samples of KBD patients, GPX1 and NF-kappaB p65 mRNA levels were lower (P<0.01) while p53 levels were higher (P<0.001). CONCLUSION GPX1 Pro198Leu is a potential genetic risk factor in the development of KBD and the GPX1 Leu allele is significantly associated with higher KBD risk among the Chinese Han population and with lower GPX enzyme activity. The expression of apoptosis related molecules in KBD patients significantly differs from controls.
Collapse
Affiliation(s)
- Y M Xiong
- Department of Pharmacology, College of Medicine, Xi'an Jiaotong University, Xi'an, Shaanxi 710061, P.R. China
| | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Santen RJ, Lobenhofer EK, Afshari CA, Bao Y, Song RX. Adaptation of estrogen-regulated genes in long-term estradiol deprived MCF-7 breast cancer cells. Breast Cancer Res Treat 2006; 94:213-23. [PMID: 16258703 DOI: 10.1007/s10549-005-5776-4] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
First line treatment of hormone dependent breast cancer initially causes tumor regression but later results in adaptive changes and tumor re-growth. Responses to second line treatments occur but tumors again begin to progress after a period of 12???18??months. In depth understanding of the adaptive process would allow the identification of targets to abrogate the development of hormonal resistance and prolong the efficacy of endocrine therapy. We have developed a model system to examine adaptive changes in human MCF-7 breast cancer cells. Upon deprivation of estradiol for a prolonged period of time, a maneuver analogous to surgical oophorectomy in pre-menopausal women and use of aromatase inhibitors in post-menopausal patients, tumor cells adapt and become hypersensitive to estradiol. We reasoned that the expression pattern of multiple genes would change in response to estradiol deprivation and that cDNA microarrays would provide an efficient means of assessing these changes. Accordingly, we examined the transcriptional responses to estradiol in long-term estradiol deprived (LTED) MCF-7 cells with a cDNA microarray containing 1901 known genes and ESTs. To assess the changes induced by long-term estradiol deprivation, we compared the effects of estradiol administration in LTED cells with those in MCF-7 cells, which we had previously reported, and confirmed with real time PCR using the parental and LTED cells. Seven genes and one EST were induced by estradiol in LTED but not in wild type MCF-7 cells, whereas ten genes were down-regulated by estradiol only in LTED cells. The expression of seven genes increased concurrently and five decreased in response to estradiol in both cell types. From these observations, we generated testable hypotheses regarding several genes including DKFZP, RAP-1, ribosomal protein S6, and TM4SF1. Based upon the known functions of these genes and the patterns of observed changes, we postulate that divergent regulation of these genes may contribute to the different biologic responses to estrogen in these cell lines. These results provide targets for further mechanistic studies in our experimental system. Our findings indicate that long-term estradiol deprivation causes expression changes in multiple genes and emphasizes the complexity of the process of cellular adaptation.
Collapse
Affiliation(s)
- R J Santen
- Division of Endocrinology, University of Virginia Health System, Charlottesville, VA 22908, USA.
| | | | | | | | | |
Collapse
|
6
|
Santen RJ, Song RX, Zhang Z, Kumar R, Jeng MH, Masamura A, Lawrence J, Berstein L, Yue W. Long-term estradiol deprivation in breast cancer cells up-regulates growth factor signaling and enhances estrogen sensitivity. Endocr Relat Cancer 2005; 12 Suppl 1:S61-73. [PMID: 16113100 DOI: 10.1677/erc.1.01018] [Citation(s) in RCA: 100] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
Deprivation of estrogen causes breast tumors in women to adapt and develop enhanced sensitivity to this steroid. Accordingly, women relapsing after treatment with oophorectomy, which substantially lowers estradiol for a prolonged period, respond secondarily to aromatase inhibitors with tumor regression. We have utilized in vitro and in vivo model systems to examine the biologic processes whereby long-term estradiol deprivation (LTED) causes cells to adapt and develop hypersensitivity to estradiol. Several mechanisms are associated with this response, including up-regulation of estrogen receptor-alpha (ERalpha) and the MAP kinase, phosphoinositol 3 kinase (PI3-K) and mammalian target of rapamycin (mTOR) growth factor pathways. ERalpha is four- to tenfold up-regulated and co-opts a classical growth factor pathway using Shc, Grb-2 and Sos. This induces rapid non-genomic effects which are enhanced in LTED cells. The molecules involved in the non-genomic signaling process have been identified. Estradiol binds to cell membrane-associated ERalpha, which physically associates with the adaptor protein Shc, and induces its phosphorylation. In turn, Shc binds Grb-2 and Sos, which result in the rapid activation of MAP kinase. These non-genomic effects of estradiol produce biologic effects as evidenced by Elk-1 activation and by morphologic changes in cell membranes. Additional effects include activation of the PI3-K and mTOR pathways through estradiol-induced binding of ERalpha to the IGF-I and epidermal growth factor receptors. A major question is how ERalpha locates in the plasma membrane since it does not contain an inherent membrane localization signal. We have provided evidence that the IGF-I receptor serves as an anchor for ERalpha in the plasma membrane. Estradiol causes phosphorylation of the adaptor protein, Shc and the IGF-I receptor itself. Shc, after binding to ERalpha, serves as the 'bus' which carries ERalpha to Shc-binding sites on the activated IGF-I receptors. Use of small inhibitor (si) RNA methodology to knockdown Shc allows the conclusion that Shc is needed for ERalpha to localize in the plasma membrane. In order to abrogate growth factor-induced hypersensitivity, we have utilized a drug, farnesylthiosalicylic acid, which blocks the binding of GTP-Ras to its membrane acceptor protein, galectin 1, and reduces the activation of MAP kinase. We have also shown that this drug is a potent inhibitor of mTOR as an additional mechanism of inhibition of cell proliferation. The concept of 'adaptive hypersensitivity' and the mechanisms responsible for this phenomenon have important clinical implications. The efficacy of aromatase inhibitors in patients relapsing on tamoxifen could be explained by this mechanism and inhibitors of growth factor pathways should reverse the hypersensitivity phenomenon and result in prolongation of the efficacy of hormonal therapy for breast cancer.
Collapse
Affiliation(s)
- R J Santen
- Department of Medicine, University of Virginia Health System, 450 Ray C Hunt Dr, Charlottesville, VA 22903, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Santen RJ, Song RX, Zhang Z, Kumar R, Jeng MH, Masamura S, Lawrence J, MacMahon LP, Yue W, Berstein L. Adaptive hypersensitivity to estrogen: mechanisms and clinical relevance to aromatase inhibitor therapy in breast cancer treatment. J Steroid Biochem Mol Biol 2005; 95:155-65. [PMID: 16024245 DOI: 10.1016/j.jsbmb.2005.04.025] [Citation(s) in RCA: 65] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Breast tumors in women can adapt to endocrine deprivation therapy by developing hypersensitivity to estradiol. For this reason, aromatase inhibitors can be effective in women relapsing after treatment with tamoxifen or following oophorectomy. To understand the mechanisms responsible, we examined estrogenic stimulation of cell proliferation in a model system and provided in vitro and in vivo evidence that long-term estradiol deprivation (LTED) causes "adaptive hypersensitivity". The primary mechanisms responsible involve up-regulation of ER alpha as well as the MAP kinase, PI-3 kinase, and mTOR growth factor pathways. ER alpha is 4-10-fold up-regulated and co-opts a classical growth factor pathway using Shc, Grb2, and Sos. This induces rapid non-genomic effects which are enhanced in LTED cells. Estradiol binds to cell membrane associated ER alpha, physically associates with the adaptor protein Shc, and induces its phosphorylation. In turn, Shc binds Grb2 and Sos which result in the rapid activation of MAP kinase. These non-genomic effects of estradiol produce biologic effects as evidenced by Elk activation and by morphologic changes in cell membranes. Additional effects include activation of PI-3 kinase and mTOR pathways through estradiol induced binding of ER alpha to the IGF-1 and EGF receptors. Further proof of the non-genomic effects of estradiol involved use of "designer" cells which selectively express ER alpha in nucleus, cytosol, and cell membrane. We have used a new downstream inhibitor of these pathways, farnesyl-thio-salicylic acid (FTS), to block proliferation in hypersensitive cells as a model for a potentially effective strategy for treatment of patients.
Collapse
Affiliation(s)
- R J Santen
- Department of Medicine, University of Virginia Health System, P.O. Box 801416, Charlottesville, VA 22908, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Santen RJ, Song RX, Zhang Z, Kumar R, Jeng MH, Masamura S, Yue W, Berstein L. Adaptive hypersensitivity to estrogen: mechanism for superiority of aromatase inhibitors over selective estrogen receptor modulators for breast cancer treatment and prevention. Endocr Relat Cancer 2003; 10:111-30. [PMID: 12790774 DOI: 10.1677/erc.0.0100111] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
Clinical observations suggest that human breast tumors can adapt to endocrine therapy by developing hypersensitivity to estradiol (E(2)). To understand the mechanisms responsible, we examined estrogenic stimulation of cell proliferation in a model system and provided in vitro and in vivo evidence that long-term E(2) deprivation (LTED) causes "adaptive hypersensitivity". The enhanced responses to E(2) do not involve mechanisms acting at the level of transcription of estrogen-regulated genes. We found no evidence of hypersensitivity when examining the effects of E(2) on regulation of c-myc, pS2, progesterone receptor, several estrogen receptor (ER) reporter genes, or c-myb in hypersensitive cells. Estrogen deprivation of breast cells long-term does up-regulate both the MAP kinase and phosphatidyl-inositol 3-kinase pathways. As a potential explanation for up-regulation of these signaling pathways, we found that ERalpha is 4- to 10-fold up-regulated and co-opts a classic growth factor pathway using Shc, Grb-2 and Sos. This induces rapid non-genomic effects which are enhanced in LTED cells. E(2) binds to cell membrane-associated ERalpha, physically associates with the adapter protein SHC, and induces its phosphorylation. In turn, Shc binds Grb-2 and Sos, which results in the rapid activation of MAP kinase. These non-genomic effects of E(2) produce biological effects as evidenced by Elk activation and by morphological changes in cell membranes. Further proof of the non-genomic effects of E(2) involved use of cells which selectively expressed ERalpha in the nucleus, cytosol and cell membrane. We created these COS-1 "designer cells" by transfecting ERalpha lacking a nuclear localization signal and containing a membrane localizing signal. The concept of "adaptive hypersensitivity" and the mechanisms responsible for this phenomenon have important clinical implications. Adaptive hypersensitivity would explain the superiority of aromatase inhibitors over the selective ER modulators (SERMs) for treatment of breast cancer. The development of highly potent third-generation aromatase inhibitors allows reduction of breast tissue E2 to very low levels and circumvents the enhanced sensitivity of these cells to the proliferative effects of E(2). Clinical trials in the adjuvant, neoadjuvant and advanced disease settings demonstrate the greater clinical efficacy of the aromatase inhibitors over the SERMs. More recent observations indicate that the aromatase inhibitors are superior for the prevention of breast cancer as well. These observations may be explained by the hypothesis that estrogens induce breast cancer both by stimulating cell proliferation and by their metabolism to genotoxic products. The SERMs block ER-mediated proliferation only, whereas the aromatase inhibitors exert dual effects on proliferation and genotoxic metabolite formation.
Collapse
Affiliation(s)
- R J Santen
- Department of Medicine, University of Virginia Health System, Charlottesville, Virginia, USA.
| | | | | | | | | | | | | | | |
Collapse
|
9
|
Abstract
Clinical observations suggest that human breast tumors can adapt in response to endocrine therapy by developing hypersensitivity to estradiol. To understand the mechanisms responsible, we examined estrogenic stimulation of cell proliferation in a model system and provided evidence that long-term deprivation of estradiol causes adaptive hypersensitivity. The enhanced responses to estradiol do not involve mechanisms acting at the level of transcription of estrogen regulated genes. We found no evidence of hypersensitivity when examining the effects of estradiol on regulation of c-myc, pS2, progesterone receptor, several ER reporter genes or c-myb in hypersensitive cells. On the other hand, deprivation of breast cells long term was found to up-regulate a separate pathway whereby the estrogen receptor co-opts a classical growth factor pathway and induces rapid non-genomic effects. Through this pathway, estradiol caused rapid activation of mitogen-activated protein (MAP) kinase. In exploring the mechanisms mediating this event, we found that estradiol binds to cell membrane associated estrogen receptors and causes phosphorylation of Shc, an adaptor protein usually involved in growth factor signaling pathways. ERalpha was found to complex with Shc under these conditions. In turn, Shc bound Grb-2 and Sos which resulted in the activation of MAP kinase. The pure antiestrogen, ICI 182,780, blocked several steps in the rapidly responding ER alpha, Shc, MAP kinase pathway. These non-genomic effects of estradiol produced biologic effects by activating Elk and by inducing morphologic changes in cell membranes. Using confocal microscopy, we demonstrated that estradiol caused a rapid alteration in membrane ruffling, the formation of pseudopodia and translocation of ER alpha to regions contiguous with the cell membrane. These morphologic effects could be blocked with a pure anti-estrogen. We conclude that long-term estradiol deprived cells utilize both genomic (transcriptional) and rapid, non-genomic estradiol induced pathways. We postulate that synergy between these two pathways acting at the level of the cell cycle is responsible for adaptive hypersensitivity.
Collapse
Affiliation(s)
- R X Song
- Department of Medicine, University of Virginia Health Sciences System, Charlottesville, VA, USA
| | | | | | | | | | | | | |
Collapse
|
10
|
Song RX, Mor G, Naftolin F, McPherson RA, Song J, Zhang Z, Yue W, Wang J, Santen RJ. Effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17beta-estradiol. J Natl Cancer Inst 2001; 93:1714-23. [PMID: 11717332 DOI: 10.1093/jnci/93.22.1714] [Citation(s) in RCA: 233] [Impact Index Per Article: 10.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
BACKGROUND High doses of estrogen can promote tumor regression in postmenopausal women with hormone-dependent breast cancer, but the mechanism is unknown. We investigated the molecular basis of this process by using LTED cells, which were derived by growing MCF-7 breast cancer cells under long-term (6-24 months) estrogen-deprived conditions. METHODS We treated LTED and MCF-7 cells with various concentrations of 17beta-estradiol (estradiol) and assayed their growth by counting the cells and measured apoptosis by annexin V staining and DNA fragmentation. Using western blot analysis, we also examined the expression of the apoptosis-inducing system of the Fas death receptor protein and its ligand, FasL, in these cells. To assess the involvement of Fas and FasL in the induction of apoptosis in LTED cells, we used activating anti-Fas antibodies and the universal caspase inhibitor Z-VAD. Finally, we examined the expression of Fas protein in E8CASS and BSK3 cells, two other cell lines derived by depriving MCF-7 cells of estrogen long term, and the responses of these cells to high-dose estradiol. All statistical tests were two-sided. RESULTS High concentrations of estradiol (>or=0.1 nM) resulted in a statistically significant, 60% reduction in the growth of LTED cells (P< .001) and in a sevenfold increase in apoptosis (P< .001) as compared with levels in vehicle-treated cells. Both LTED and MCF-7 cells expressed FasL, but only LTED cells expressed Fas. Treatment of LTED cells with 0.1 nM estradiol increased the expression of FasL. Activating anti-Fas antibodies increased apoptosis of LTED cells, which was further stimulated by estradiol. Z-VAD blocked estradiol-induced apoptosis. E8CASS cells, which express Fas protein, but not BSK3 cells, which do not, also responded to 0.1 nM estradiol by increasing apoptosis. CONCLUSION Tumor regression induced by high-dose estrogen therapy in postmenopausal woman may result from estrogen activation of Fas-mediated apoptosis.
Collapse
Affiliation(s)
- R X Song
- Department of Internal Medicine, University of Virginia School of Medicine, Charlottesville, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Zhou SW, Xu FD, Li SM, Song RX, Qi S, Zhang Y, Bao YP. Major origin of mutagenicity of chlorinated drinking water in China: humic acid or pollutants. Sci Total Environ 1997; 196:191-196. [PMID: 9141714 DOI: 10.1016/s0048-9697(96)05399-5] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/22/2023]
Abstract
Since Loper and Glatz (J. Toxicol. Environ. Health, 4:919-938;1978) discovered the presence of the mutagenicity in drinking water after chlorination in 1978, humic acid (HA) has been considered as an important source. But our research results show that only 1/8 of observed direct frameshift mutagenicity in tap water originated from chlorination of HA isolated from raw water. Contamination from industrial waste and human settlement (night soil) are important potential sources of mutagenicity in chlorinated drinking water. The results show that mutagenicity from night soil after chlorination depended upon pH of sample. Production of mutagenicity at pH 6 is ten times of that at pH 8, and decomposition process is necessary condition for mutagenicity production. Season variation of mutagenicity of tap is also presented in the paper.
Collapse
Affiliation(s)
- S W Zhou
- Chinese Academy for Preventive Medicine, Shanghai Institute of Environmental Health Monitoring, China
| | | | | | | | | | | | | |
Collapse
|